Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| 2.21 | |
| 2.21 | |
| - | |
| 2.21 | |
| 2.21 | |
| 1.8505-7.586 | |
| 289 M | |
| 114 M | |
| 12 317 K | |
| 1.836 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Fate Therapeutics (FATE) shares rallied 25.4% in the last trading session to close at $5.72. This move can be attributable to notable volume with a higher number of shares being traded than in a typic...
Fate Therapeutics, Inc. iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase 1 Study is Being...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
